FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206197791> ?p ?o ?g. }

• W4206197791 abstract "Purpose The aim of the study was to delineate the disease characteristics, the initial treatment patterns, and survival in patients with mantle cell lymphoma (MCL) managed in the real world. Methods Data of 518 MCL patients from 5 major Chinese Hematology Centers in the period from 2007 to 2017 were retrospectively analyzed. Results The median age was 58 years. Of the patients, 88.6% had Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0–1 and 80.7% had advanced-stage disease. Ki67 expression was &lt;30% in 39.6% of the patients, and 43.2% of patients were categorized into a low-risk group based on the Mantle Cell Lymphoma International Prognostic Index (MIPI) scoring system. Overall, 73.4% of the patients received rituximab as their first-line therapy. The most commonly used chemotherapy was the CHOP-like (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) regimen (45.2%), followed by high-dose cytarabine-containing chemotherapy (31.3%) and bendamustine (3.3%). Of the patients, 13.7% ( n = 71) underwent consolidative autologous stem cell transplantation (ASCT), and 19.3% ( n = 100) received novel agents containing first-line regimens. With a median follow-up time of 52 months, the 3- and 5-year overall survival (OS) rates were 73.7% and 61.4%, respectively. Age ≤60 years, ECOG PS 0–1, stages I–II, normal lactate dehydrogenase (LDH), absence of bone marrow involvement, Ki67 &lt;30%, and lower-risk IPI/MIPI scores were significantly associated with improved OS ( p &lt; 0.05). The inclusion of rituximab improved the 5-year OS, with borderline significance (62.5% vs . 55.2%, p = 0.076). High-dose cytarabine-containing chemotherapy showed significant clinical benefit in 5-year OS (72.1% vs . 55.9%, p = 0.010). Patients with ASCT had better 5-year OS in the younger (≤60 years) age group (87.2% vs . 64.8%, p = 0.002). Conclusion This large retrospective dataset unequivocally confirmed the survival advantage afforded by cytarabine-containing regimen and ASCT in a first-line setting under real-world management in the rituximab era." @default.
• W4206197791 created "2022-01-25" @default.
• W4206197791 creator A5006739024 @default.
• W4206197791 creator A5010045617 @default.
• W4206197791 creator A5021146920 @default.
• W4206197791 creator A5030040961 @default.
• W4206197791 creator A5037562417 @default.
• W4206197791 creator A5038280418 @default.
• W4206197791 creator A5044794520 @default.
• W4206197791 creator A5054231625 @default.
• W4206197791 creator A5059679868 @default.
• W4206197791 creator A5066795023 @default.
• W4206197791 creator A5067212579 @default.
• W4206197791 creator A5069739901 @default.
• W4206197791 creator A5072709319 @default.
• W4206197791 creator A5076360288 @default.
• W4206197791 date "2022-01-04" @default.
• W4206197791 modified "2023-09-29" @default.
• W4206197791 title "Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study" @default.
• W4206197791 cites W1549556227 @default.
• W4206197791 cites W1829587101 @default.
• W4206197791 cites W2007748783 @default.
• W4206197791 cites W2026122699 @default.
• W4206197791 cites W2051648120 @default.
• W4206197791 cites W2076257589 @default.
• W4206197791 cites W2124235514 @default.
• W4206197791 cites W2151092645 @default.
• W4206197791 cites W2158945674 @default.
• W4206197791 cites W2162109567 @default.
• W4206197791 cites W2169209759 @default.
• W4206197791 cites W2177017987 @default.
• W4206197791 cites W2184668473 @default.
• W4206197791 cites W2189740376 @default.
• W4206197791 cites W2310716991 @default.
• W4206197791 cites W2430862255 @default.
• W4206197791 cites W2470400696 @default.
• W4206197791 cites W2495508741 @default.
• W4206197791 cites W2518731208 @default.
• W4206197791 cites W2608724752 @default.
• W4206197791 cites W2726940470 @default.
• W4206197791 cites W2760635695 @default.
• W4206197791 cites W2774522106 @default.
• W4206197791 cites W2790333200 @default.
• W4206197791 cites W2892160172 @default.
• W4206197791 cites W2906765096 @default.
• W4206197791 cites W2917537905 @default.
• W4206197791 cites W2937620616 @default.
• W4206197791 cites W2991957155 @default.
• W4206197791 cites W3029266545 @default.
• W4206197791 cites W3097326242 @default.
• W4206197791 doi "https://doi.org/10.3389/fonc.2021.770988" @default.
• W4206197791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35059312" @default.
• W4206197791 hasPublicationYear "2022" @default.
• W4206197791 type Work @default.
• W4206197791 citedByCount "3" @default.
• W4206197791 countsByYear W42061977912022 @default.
• W4206197791 countsByYear W42061977912023 @default.
• W4206197791 crossrefType "journal-article" @default.
• W4206197791 hasAuthorship W4206197791A5006739024 @default.
• W4206197791 hasAuthorship W4206197791A5010045617 @default.
• W4206197791 hasAuthorship W4206197791A5021146920 @default.
• W4206197791 hasAuthorship W4206197791A5030040961 @default.
• W4206197791 hasAuthorship W4206197791A5037562417 @default.
• W4206197791 hasAuthorship W4206197791A5038280418 @default.
• W4206197791 hasAuthorship W4206197791A5044794520 @default.
• W4206197791 hasAuthorship W4206197791A5054231625 @default.
• W4206197791 hasAuthorship W4206197791A5059679868 @default.
• W4206197791 hasAuthorship W4206197791A5066795023 @default.
• W4206197791 hasAuthorship W4206197791A5067212579 @default.
• W4206197791 hasAuthorship W4206197791A5069739901 @default.
• W4206197791 hasAuthorship W4206197791A5072709319 @default.
• W4206197791 hasAuthorship W4206197791A5076360288 @default.
• W4206197791 hasBestOaLocation W42061977911 @default.
• W4206197791 hasConcept C126322002 @default.
• W4206197791 hasConcept C141071460 @default.
• W4206197791 hasConcept C143998085 @default.
• W4206197791 hasConcept C2776694085 @default.
• W4206197791 hasConcept C2776755627 @default.
• W4206197791 hasConcept C2776907518 @default.
• W4206197791 hasConcept C2777525834 @default.
• W4206197791 hasConcept C2778041864 @default.
• W4206197791 hasConcept C2778336483 @default.
• W4206197791 hasConcept C2778476033 @default.
• W4206197791 hasConcept C2779050716 @default.
• W4206197791 hasConcept C2779338263 @default.
• W4206197791 hasConcept C2779429289 @default.
• W4206197791 hasConcept C2779725641 @default.
• W4206197791 hasConcept C2780653079 @default.
• W4206197791 hasConcept C2781413609 @default.
• W4206197791 hasConcept C2781442060 @default.
• W4206197791 hasConcept C2911091166 @default.
• W4206197791 hasConcept C71924100 @default.
• W4206197791 hasConcept C90924648 @default.
• W4206197791 hasConceptScore W4206197791C126322002 @default.
• W4206197791 hasConceptScore W4206197791C141071460 @default.
• W4206197791 hasConceptScore W4206197791C143998085 @default.
• W4206197791 hasConceptScore W4206197791C2776694085 @default.
• W4206197791 hasConceptScore W4206197791C2776755627 @default.
• W4206197791 hasConceptScore W4206197791C2776907518 @default.
• W4206197791 hasConceptScore W4206197791C2777525834 @default.

• next